Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Genetics and Genomics›Reverse Genetics
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Reverse Genetics

Genetics and Genomics · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 4 min read

The use of techniques that produce a functional mutation or an effect on gene expression of a specific gene of interest in order to identify the role or activity of the gene product of that gene.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (819 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

The use of techniques that produce a functional mutation or an effect on gene expression of a specific gene of interest in order to identify the role or activity of the gene product of that gene.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Genetics, Reverse.

Where it fits in the MeSH classification

Broader topics
Genetic Techniques

Related concepts

  • Mutation
  • Gene Expression

Research landscape

PubMed indexes 1,277 records tagged with the MeSH heading “Reverse Genetics” (counts retrieved 2026-10-29). 436 of them (34.1%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 852 records.

Reviews account for 200 records (15.7%) and meta-analyses for 1. Randomized controlled trials number 2 (0.2%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 0 records; 2000-2009: 0 records; 2010-2019: 852 records; 2020 onward: 436 records0through 199902000-20098522010-20194362020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19990
2000-20090
2010-2019852
2020 onward436
Share of records by publication typeReviews: 15.7 percent; Meta-analyses: 0.1 percent; Randomized controlled trials: 0.2 percentReviews15.7% (200)Meta-analyses0.1% (1)Randomized controlled trials0.2% (2)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 1,277 PubMed records
TypeRecordsShare
Reviews20015.7%
Meta-analyses10.1%
Randomized controlled trials20.2%

Method: PubMed query "Reverse Genetics"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in genetics and genomics

Genetic findings vary widely in strength. A variant linked to a condition in one study may not replicate in other ancestries, and most common variants have small effects that are meaningful only in aggregate. Studies of rare, high-impact variants can support strong causal claims about a gene, while association studies describe statistical links that need functional and independent replication. Check the sample size, the ancestry of participants, whether results were replicated, and whether a laboratory or clinical outcome was actually measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research
Rihn SJ, Merits A, Bakshi S, Turnbull ML, Wickenhagen A, Alexander AJT, et al.
2021Research article
Design not recorded in structured metadata
215cc by
PMID 33630831 · DOI · PMC7906417
Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction
Torii S, Ono C, Suzuki R, Morioka Y, Anzai I, Fauzyah Y, et al.
2021Research article
Design not recorded in structured metadata
170cc by
PMID 33838744 · DOI · PMC8015404
A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses
Amarilla AA, Sng JDJ, Parry R, Deerain JM, Potter JR, Setoh YX, et al.
2021Research article
Design not recorded in structured metadata
156cc by
PMID 34103499 · DOI · PMC8187723
Application of the CPER reverse genetics system for genetic engineering of rabies virus
Itakura Y, Kawaguchi N, Tabata K, Gonzalez G, Konishi K, Ohnuma A, et al.
2026Research article
Design not recorded in structured metadata
3cc by
PMID 41823415 · DOI · PMC13098199

A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research [1]

Research article Rihn SJ, Merits A, Bakshi S, Turnbull ML, Wickenhagen A, Alexander AJT, et al. · · 2021 · cited 215 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The recent emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the underlying cause of Coronavirus Disease 2019 (COVID-19), has led to a worldwide pandemic causing substantial morbidity, mortality, and economic devastation.
Closing excerpt
bio/, constitutes a resource with considerable potential to advance COVID-19 vaccine design, drug testing, and discovery science.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (201 words)

The recent emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the underlying cause of Coronavirus Disease 2019 (COVID-19), has led to a worldwide pandemic causing substantial morbidity, mortality, and economic devastation. In response, many laboratories have redirected attention to SARS-CoV-2, meaning there is an urgent need for tools that can be used in laboratories unaccustomed to working with coronaviruses. Here we report a range of tools for SARS-CoV-2 research. First, we describe a facile single plasmid SARS-CoV-2 reverse genetics system that is simple to genetically manipulate and can be used to rescue infectious virus through transient transfection (without in vitro transcription or additional expression plasmids). The rescue system is accompanied by our panel of SARS-CoV-2 antibodies (against nearly every viral protein), SARS-CoV-2 clinical isolates, and SARS-CoV-2 permissive cell lines, which are all openly available to the scientific community. Using these tools, we demonstrate here that the controversial ORF10 protein is expressed in infected cells. Furthermore, we show that the promising repurposed antiviral activity of apilimod is dependent on TMPRSS2 expression. Altogether, our SARS-CoV-2 toolkit, which can be directly accessed via our website at https://mrcppu-covid.bio/, constitutes a resource with considerable potential to advance COVID-19 vaccine design, drug testing, and discovery science.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 33630831 · DOI · PMC7906417

Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction [2]

Research article Torii S, Ono C, Suzuki R, Morioka Y, Anzai I, Fauzyah Y, et al. · · 2021 · cited 170 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the causative agent of coronavirus disease 2019 (COVID-19).
Closing excerpt
This reverse genetics system may potentially advance further understanding of SARS-CoV-2.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (144 words)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the causative agent of coronavirus disease 2019 (COVID-19). Although multiple mutations have been observed in SARS-CoV-2, functional analysis of each mutation of SARS-CoV-2 has been limited by the lack of convenient mutagenesis methods. In this study, we establish a PCR-based, bacterium-free method to generate SARS-CoV-2 infectious clones. Recombinant SARS-CoV-2 could be rescued at high titer with high accuracy after assembling 10 SARS-CoV-2 cDNA fragments by circular polymerase extension reaction (CPER) and transfection of the resulting circular genome into susceptible cells. The construction of infectious clones for reporter viruses and mutant viruses could be completed in two simple steps: introduction of reporter genes or mutations into the desirable DNA fragments (∼5,000 base pairs) by PCR and assembly of the DNA fragments by CPER. This reverse genetics system may potentially advance further understanding of SARS-CoV-2.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 33838744 · DOI · PMC8015404

A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses [3]

Research article Amarilla AA, Sng JDJ, Parry R, Deerain JM, Potter JR, Setoh YX, et al. · · 2021 · cited 156 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The current COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Closing excerpt
Additionally, reporter and mutant viruses are generated and employed to study virus replication and virus-receptor interactions.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (157 words)

The current COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We demonstrate that despite the large size of the viral RNA genome (~30 kb), infectious full-length cDNA is readily assembled in vitro by a circular polymerase extension reaction (CPER) methodology without the need for technically demanding intermediate steps. Overlapping cDNA fragments are generated from viral RNA and assembled together with a linker fragment containing CMV promoter into a circular full-length viral cDNA in a single reaction. Transfection of the circular cDNA into mammalian cells results in the recovery of infectious SARS-CoV-2 virus that exhibits properties comparable to the parental virus in vitro and in vivo. CPER is also used to generate insect-specific Casuarina virus with ~20 kb genome and the human pathogens Ross River virus (Alphavirus) and Norovirus (Calicivirus), with the latter from a clinical sample. Additionally, reporter and mutant viruses are generated and employed to study virus replication and virus-receptor interactions.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34103499 · DOI · PMC8187723

Application of the CPER reverse genetics system for genetic engineering of rabies virus [4]

Research article Itakura Y, Kawaguchi N, Tabata K, Gonzalez G, Konishi K, Ohnuma A, et al. · · 2026 · cited 3 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Reverse genetics (RG) systems are essential tools for basic virological studies and applied studies using engineered recombinant viruses in various research fields.
Closing excerpt
Our approach greatly facilitates genetic engineering of RABV and provides a versatile framework that can be extended to other mononegaviruses, thereby accelerating both basic and applied virology research.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (317 words)

Reverse genetics (RG) systems are essential tools for basic virological studies and applied studies using engineered recombinant viruses in various research fields. While the circular polymerase extension reaction (CPER) has been widely applied to prepare a full-length infectious complementary DNA (cDNA) of positive-sense RNA viruses, its use for negative-sense RNA viruses (mononegaviruses) remains limited. Here, we report the first CPER-based RG system for rabies virus (RABV), a member of mononegaviruses. Infectious RABV was successfully rescued from cells transfected with helper plasmids and the CPER product, the assembled overlapping DNA fragments encoding the full-length viral genome cDNA and regulatory elements. Using this system, we generated wild-type, point-mutant, reporter-expressing, and chimeric RABVs, all of which retained their expected biological properties. Deep sequencing revealed that CPER-derived viruses occasionally harbor low-frequency mutations undetectable by Sanger sequencing, highlighting PCR-related artifacts as a limitation. In addition, CPER products with a pUC19 backbone could be directly applied for Escherichia coli transformation and cloning of RABV full-genome cDNA plasmids, offering a flexible, ligase-free cloning strategy for conventional RG. Our work establishes CPER as a versatile platform for engineering recombinant RABVs, facilitating rapid generation and genetic manipulation of RABV with potential applications for research on other mononegaviruses.IMPORTANCEReverse genetics systems allow researchers to generate recombinant viruses with precise genetic modifications, advancing studies of viral replication, pathogenicity, and vaccine development. However, constructing a full-length viral genome expressing plasmids is often time-consuming and technically demanding. To bypass the cloning process, a simple, cloning-free reverse genetics platform based on the circular polymerase extension reaction (CPER) has been applied for positive-sense RNA viruses. In this study, we applied the CPER-based reverse genetics system for rabies virus (RABV), a mononegavirus, enabling rapid and flexible generation of recombinant RABVs, including mutant, reporter-expressing, and chimeric clones. Our approach greatly facilitates genetic engineering of RABV and provides a versatile framework that can be extended to other mononegaviruses, thereby accelerating both basic and applied virology research.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41823415 · DOI · PMC13098199

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Engineering SARS-CoV-2 using a reverse genetic system [5]
    Xie X, Lokugamage KG, Zhang X, Vu MN, Muruato AE, Menachery VD, et al. · Nat Protoc · 2021 · cited 179 times (Europe PMC)
  • Research article Developing vaccines in the era of genomics: a decade of reverse vaccinology [6]
    Seib KL, Zhao X, Rappuoli R · Clin Microbiol Infect · 2012 · cited 126 times (Europe PMC)
  • Research article Flavivirus reverse genetic systems, construction techniques and applications: a historical perspective [7]
    Aubry F, Nougairède A, Gould EA, de Lamballerie X · Antiviral Res · 2015 · cited 121 times (Europe PMC)
  • Research article TILLING: a shortcut in functional genomics [8]
    Kurowska M, Daszkowska-Golec A, Gruszka D, Marzec M, Szurman M, Szarejko I, et al. · J Appl Genet · 2011 · cited 116 times (Europe PMC)
  • Research article A Natural Product Chemist's Guide to Unlocking Silent Biosynthetic Gene Clusters [9]
    Covington BC, Xu F, Seyedsayamdost MR · Annu Rev Biochem · 2021 · cited 112 times (Europe PMC)
  • Research article Coronavirus reverse genetic systems: infectious clones and replicons [10]
    Almazán F, Sola I, Zuñiga S, Marquez-Jurado S, Morales L, Becares M, et al. · Virus Res · 2014 · cited 109 times (Europe PMC)

References

  1. Rihn SJ, Merits A, Bakshi S, Turnbull ML, Wickenhagen A, Alexander AJT, et al.. A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. . 2021. PMID 33630831 · DOI · PMC7906417
  2. Torii S, Ono C, Suzuki R, Morioka Y, Anzai I, Fauzyah Y, et al.. Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction. . 2021. PMID 33838744 · DOI · PMC8015404
  3. Amarilla AA, Sng JDJ, Parry R, Deerain JM, Potter JR, Setoh YX, et al.. A versatile reverse genetics platform for SARS-CoV-2 and other positive-strand RNA viruses. . 2021. PMID 34103499 · DOI · PMC8187723
  4. Itakura Y, Kawaguchi N, Tabata K, Gonzalez G, Konishi K, Ohnuma A, et al.. Application of the CPER reverse genetics system for genetic engineering of rabies virus. . 2026. PMID 41823415 · DOI · PMC13098199
  5. Xie X, Lokugamage KG, Zhang X, Vu MN, Muruato AE, Menachery VD, et al.. Engineering SARS-CoV-2 using a reverse genetic system. Nat Protoc. 2021. PMID 33514944 · DOI · PMC8168523
  6. Seib KL, Zhao X, Rappuoli R. Developing vaccines in the era of genomics: a decade of reverse vaccinology. Clin Microbiol Infect. 2012. PMID 22882709 · DOI
  7. Aubry F, Nougairède A, Gould EA, de Lamballerie X. Flavivirus reverse genetic systems, construction techniques and applications: a historical perspective. Antiviral Res. 2015. PMID 25512228 · DOI · PMC7173292
  8. Kurowska M, Daszkowska-Golec A, Gruszka D, Marzec M, Szurman M, Szarejko I, et al.. TILLING: a shortcut in functional genomics. J Appl Genet. 2011. PMID 21912935 · DOI · PMC3189332
  9. Covington BC, Xu F, Seyedsayamdost MR. A Natural Product Chemist's Guide to Unlocking Silent Biosynthetic Gene Clusters. Annu Rev Biochem. 2021. PMID 33848426 · DOI · PMC9148385
  10. Almazán F, Sola I, Zuñiga S, Marquez-Jurado S, Morales L, Becares M, et al.. Coronavirus reverse genetic systems: infectious clones and replicons. Virus Res. 2014. PMID 24930446 · DOI · PMC4727449

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Gene Expression RegulationGenetics and Genomics
  • Gene ExpressionGenetics and Genomics
  • Gene AmplificationGenetics and Genomics
  • Gene Expression ProfilingGenetics and Genomics
  • Gene TargetingGenetics and Genomics
  • Gene PoolGenetics and Genomics

All 95 articles in Genetics and Genomics →

At a glance

1,277
PubMed records on this heading
34%
published since 2020
200
review articles
2
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Gene Expression RegulationGenetics and Genomics
  • Gene ExpressionGenetics and Genomics
  • Gene AmplificationGenetics and Genomics
  • Gene Expression ProfilingGenetics and Genomics
  • Gene TargetingGenetics and Genomics

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support